These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30212196)

  • 1. Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs.
    Shultz MD
    J Med Chem; 2019 Feb; 62(4):1701-1714. PubMed ID: 30212196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular inflation, attrition and the rule of five.
    Leeson PD
    Adv Drug Deliv Rev; 2016 Jun; 101():22-33. PubMed ID: 26836397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates.
    Doak BC; Over B; Giordanetto F; Kihlberg J
    Chem Biol; 2014 Sep; 21(9):1115-42. PubMed ID: 25237858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating physiochemical properties of FDA-approved orally administered drugs.
    Reese TC; Devineni A; Smith T; Lalami I; Ahn JM; Raj GV
    Expert Opin Drug Discov; 2024 Feb; 19(2):225-238. PubMed ID: 37921049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five.
    Stegemann S; Moreton C; Svanbäck S; Box K; Motte G; Paudel A
    Drug Discov Today; 2023 Feb; 28(2):103344. PubMed ID: 36442594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions.
    Lipinski CA
    Adv Drug Deliv Rev; 2016 Jun; 101():34-41. PubMed ID: 27154268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution of synthetic oral drug properties.
    Proudfoot JR
    Bioorg Med Chem Lett; 2005 Feb; 15(4):1087-90. PubMed ID: 15686918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facts, Patterns, and Principles in Drug Discovery: Appraising the Rule of 5 with Measured Physicochemical Data.
    Tinworth CP; Young RJ
    J Med Chem; 2020 Sep; 63(18):10091-10108. PubMed ID: 32324397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Property distribution of drug-related chemical databases.
    Oprea TI
    J Comput Aided Mol Des; 2000 Mar; 14(3):251-64. PubMed ID: 10756480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development.
    Gill AL; Verdonk M; Boyle RG; Taylor R
    Curr Top Med Chem; 2007; 7(14):1408-22. PubMed ID: 17692029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Going further than Lipinski's rule in drug design.
    Walters WP
    Expert Opin Drug Discov; 2012 Feb; 7(2):99-107. PubMed ID: 22468912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rule of five should not impede anti-parasitic drug development.
    McKerrow JH; Lipinski CA
    Int J Parasitol Drugs Drug Resist; 2017 Aug; 7(2):248-249. PubMed ID: 28623818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target-Based Evaluation of "Drug-Like" Properties and Ligand Efficiencies.
    Leeson PD; Bento AP; Gaulton A; Hersey A; Manners EJ; Radoux CJ; Leach AR
    J Med Chem; 2021 Jun; 64(11):7210-7230. PubMed ID: 33983732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipophilic Permeability Efficiency Reconciles the Opposing Roles of Lipophilicity in Membrane Permeability and Aqueous Solubility.
    Naylor MR; Ly AM; Handford MJ; Ramos DP; Pye CR; Furukawa A; Klein VG; Noland RP; Edmondson Q; Turmon AC; Hewitt WM; Schwochert J; Townsend CE; Kelly CN; Blanco MJ; Lokey RS
    J Med Chem; 2018 Dec; 61(24):11169-11182. PubMed ID: 30395703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space.
    Meanwell NA
    Chem Res Toxicol; 2016 Apr; 29(4):564-616. PubMed ID: 26974882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of drug-like concepts on decision-making in medicinal chemistry.
    Leeson PD; Springthorpe B
    Nat Rev Drug Discov; 2007 Nov; 6(11):881-90. PubMed ID: 17971784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of physicochemical and molecular properties in drug design: navigation in the "drug-like" chemical space.
    Vallianatou T; Giaginis C; Tsantili-Kakoulidou A
    Adv Exp Med Biol; 2015; 822():187-94. PubMed ID: 25416989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption matters: A closer look at popular oral bioavailability rules for drug approvals.
    Caminero Gomes Soares A; Marques Sousa GH; Calil RL; Goulart Trossini GH
    Mol Inform; 2023 Nov; 42(11):e202300115. PubMed ID: 37550251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality guidelines for oral drug candidates: dose, solubility and lipophilicity.
    Bayliss MK; Butler J; Feldman PL; Green DV; Leeson PD; Palovich MR; Taylor AJ
    Drug Discov Today; 2016 Oct; 21(10):1719-1727. PubMed ID: 27423371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.